Ezetimibe effect on bone mineral density and markers of bone formation and resorption

Journal of Investigative Medicine

Volumn 58, Issue 2, 2010, Pages 295-297

  Sertbas, Yasar ^a   Ersoy, Ugur ^b   Ayter, Meltem ^a   Tirtil, Filiz Gultekin ^a   Kucukkaya, Belgin ^a  

^a Fatih Sultan Mehmet Teaching and Research Hospital   (Turkey)

^b HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bone mineral density; Ezetimibe; Hyperlipidemia

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CHOLESTEROL; COLLAGEN TYPE 1; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE; TRIACYLGLYCEROL;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OSSIFICATION; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ALKALINE PHOSPHATASE; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; PEPTIDE FRAGMENTS;

EID: 77950672667     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181c9af4b     Document Type: Article

References (11)

1. Edwards CJ, Russell RG, Spector TD. Statins and bone: myth or reality? Calcif Tissue Int. 2001;69(2):63-66.
2. Miwa S, Watada H, Omura C, et al. Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients. Endocr J. 2005;52(2): 259-264. (Pubitemid 40745717)
3. Staal A, Frith JC, French MH, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res. 2003;18(1):88-96. (Pubitemid 36008343)
4. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996; 347(8994):102-103.
5. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins science. 1999;286(5446):1946-1949.
6. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111(18):2356-2363. (Pubitemid 40647072)
7. Safaei H, Janghorbani M, Aminorroaya A, et al. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007;44(2):76-82. (Pubitemid 46835449)
8. Uzzan B, Cohen R, Nicolas P, et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone. 2007;40(6): 1581-1587. (Pubitemid 46779004)
9. Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7(6):469-471. (Pubitemid 351729203)
10. Charlton-Menys V, Durrington P. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93(1):27-42. (Pubitemid 350293976)
11. Välimäki MJ, Farrerons-Minguella J, Halse J, et al. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007;29(9):1937-1949. (Pubitemid 350212808)